DelveInsight has launched a new report on “Prurigo Nodularis – Market Insights, Epidemiology, and Market Forecast-2030”.
DelveInsight’s “Prurigo Nodularis – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Prurigo Nodularis, historical and forecasted epidemiology as well as the Prurigo Nodularis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the Prurigo Nodularis Market Report:
The total diagnosed prevalent population of PN in the 7MM was found to be 550,036
The United States had the largest share in the total diagnosed prevalent patient population in the 7MM, acquiring ~46.67% of the total cases in 2020.
Japan had 83,640 patients affected with PN in 2020, which is expected to increase in the forecast period (2020-2030).
Key benefits of the report:
Prurigo nodularis market report covers a descriptive overview and comprehensive insight of the Prurigo Nodularis Epidemiology and Prurigo Nodularis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
The Prurigo Nodularis market report provides insights on the current and emerging therapies.
Prurigo nodularis market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Prurigo Nodularis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Prurigo Nodularis market.
Prurigo Nodularis Overview
Prurigo nodularis (PN) is an intensely pruritic, chronic skin condition characterized by localized or generalized hyperkeratotic papules and nodules typically in a symmetrical distribution. PN is accompanied by long-standing pruritus and is thought to develop as a reaction to repeated scratching in patients with Chronic Prurigo (CP) from various etiologies, including dermatological, systemic, infectious, and psychiatric.
Prurigo Nodularis Market
The dynamics of the Prurigo Nodularis market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Menlo Therapeutics, Trevi Therapeutics, Galderma, Sanofi/ Regeneron, Amgen, Kiniksa Pharmaceuticals, Maruho, and others during the forecasted period 2018-2030.
Learn more by requesting for sample @ Prurigo Nodularis Market Landscape
Prurigo Nodularis Pipeline Therapies and Key Companies
Serlopitant :Menlo Therapeutics
Nalbuphine ER: Trevi Therapeutics
M118103:Maruho, and others
Prurigo Nodularis Market Drivers
Pipeline Advancements and various off-label therapies
Growth in Research and Development
Increase in the number of patients
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Prurigo Nodularis Patient Share (%) Overview at a Glance
5. Prurigo Nodularis Market Overview at a Glance
6. Prurigo Nodularis Disease Background and Overview
7. Prurigo Nodularis Epidemiology and Patient Population
8. Country-Specific Patient Population of Prurigo Nodularis
9. Prurigo Nodularis Current Treatment and Medical Practices
10. Unmet Needs
11. Prurigo Nodularis Emerging Therapies
12. Prurigo Nodularis Market Outlook
13. Country-Wise Prurigo Nodularis Market Analysis (2018–2030)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
18. Prurigo Nodularis Report Methodology
19. DelveInsight Capabilities
21. About DelveInsight
Click here to read more about Prurigo Nodularis Market Outlook 2030
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States